Profilo
Michel Janicot worked as a Senior Director in Oncology Scientific Licensing at Johnson & Johnson and as a Senior Director in Research & Development at Janssen, Inc. Prior to that, he was the Head of Preclinical Research & Development at Isarna Therapeutics GmbH.
He also worked as a Principal at Rhone-Poulenc Rorer Pharmaceuticals, Inc. Dr. Janicot earned a doctorate degree from Université Paris Diderot-Paris 7 in 1988.
Precedenti posizioni note di Michel Janicot
| Società | Posizione | Fine |
|---|---|---|
Janssen, Inc.
 Janssen, Inc. Pharmaceuticals: MajorHealth Technology Janssen, Inc. operates as a pharmaceutical company of Johnson & Johnson. Its products include Caelyx, Concerta, Cyclen, Ditropan XL, Duragesic, Edurant, Evra, Galexos, Invega, Invokana, Jurnista, Livostin, Pariet, Remicade, Sylvant, Topamax, Ultram, Velcade, Yondelis, and Zytiga. The company is headquartered in Toronto, Canada. | Direttore Tecnico/Scientifico/R&S | - |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
| Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
Isarna Therapeutics GmbH
 Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Michel Janicot
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| Aziende private | 4 |
|---|---|
| Université Paris Diderot-Paris 7 | Consumer Services |
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Health Technology |
| Rhone-Poulenc Rorer Pharmaceuticals, Inc. | |
Janssen, Inc.
Janssen, Inc. Pharmaceuticals: MajorHealth Technology Janssen, Inc. operates as a pharmaceutical company of Johnson & Johnson. Its products include Caelyx, Concerta, Cyclen, Ditropan XL, Duragesic, Edurant, Evra, Galexos, Invega, Invokana, Jurnista, Livostin, Pariet, Remicade, Sylvant, Topamax, Ultram, Velcade, Yondelis, and Zytiga. The company is headquartered in Toronto, Canada. | Health Technology |
- Borsa valori
- Insiders
- Michel Janicot
